Zealand Pharma A/S (ZEAL)
| Market Cap | 603.90M |
| Revenue (ttm) | 44.33M |
| Net Income (ttm) | -154.27M |
| Shares Out | 43.63M |
| EPS (ttm) | -3.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,211 |
| Open | 12.96 |
| Previous Close | 12.79 |
| Day's Range | 12.96 - 13.84 |
| 52-Week Range | 9.93 - 34.30 |
| Beta | 1.25 |
| Analysts | Buy |
| Price Target | 31.56 (+128.0%) |
| Earnings Date | May 12, 2022 |
About ZEAL
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon du...
Financial Performance
In 2021, Zealand Pharma's revenue was 292.57 million, a decrease of -17.19% compared to the previous year's 353.31 million. Losses were -1.02 billion, 20.2% more than in 2020.
Financial numbers in millions DKKFinancial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price forecast is 31.56, which is an increase of 128.03% from the latest price.
News
Zealand Pharma launches long-term incentive program for Zealand's Corporate Management and employees for 2022
Company announcement – No. 23 / 20 2 2
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Company announcement – No. 24 / 20 2 2
Why Zealand Pharma Shares Are Rising
Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital...
Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher
Zealand Pharma A/S (NASDAQ: ZEAL) has announced topline results from its second Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI), a condition in which individual...
Zealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babies
U.S.-listed shares of Zealand Pharma ZEAL, +1.83% ZEAL, +18.99% soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment for...
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hy...
Company announcement – No. 22 / 20 2 2
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
Company announcement – No. 21 / 202 2
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
Company announcement – No. 20 / 20 2 2
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Company announcement – No. 19 / 20 2 2
Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development
Company announcement – No. 18 / 2022
Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company's Refocused Strategy
C ompany a nnouncement – No. 16 / 202 2
Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022
Company announcement – No. 15 / 2022
Zealand Pharma launches long-term incentive program for Zealand's Board of Directors for 2022
Company announcement – No. 14 / 20 2 2
Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022
Company announcement – No. 13 / 202 2
Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022
Company announcement – No. 13 / 202 2
Zealand Pharma's Annual General Meeting 2022
Company announcement – No. 12 / 20 2 2
Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference
Company announcement – No. 11 / 202 2
Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Stre...
Company announcement – No. 10 / 2022
Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data f...
Company announcement – No. 9 / 202 2
Zealand Pharma convenes its Annual General Meeting 2022
Company Announcement – No. 8 / 20 2 2
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglut...
Company announcement – No. 7 / 202 2
Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021
Company announcement – No. 6 / 2022
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022
Company announcement – No. 5 / 2022
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)
Company announcement – No. 4 / 2022
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.